Galenica and Fresenius' joint venture expands portfolio

Galenica and Fresenius Medical Care’s joint venture company, Vifor Fresenius Medical Care Renal Pharma, is expanding its product portfolio and will establish a marketing and sales organization in Europe.

In addition to Ferinject (ferric carboxymaltose) and Venofer (iron sucrose) for use in nephrology indications, as well as the phosphate binder Velphoro (ferric oxhydroxide), the company will acquire nephrology medicines commercialized by Fresenius Medical Care. This will include the phosphate binders Osvaren (calcium acetate and magnesium carbonate) and Phosphosorb (calcium acetate). The companies have not disclosed financial terms, and the transfer of the marketing rights will be completed by the end of 2015.

The portfolio and the European Union marketing authorization for Velphoro granted in August 2014 means Vifor Fresenius can now develop its sales and marketing organization in key European markets.